CD36 as a double-edged sword in cancer

被引:6
|
作者
Jiang, Muwei [1 ]
Karsenberg, Renske [1 ]
Bianchi, Frans [1 ]
Bogaart, Geert van den [1 ]
机构
[1] Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Mol Immunol, Nijenborgh 7, Groningen, Netherlands
基金
欧洲研究理事会;
关键词
CD36; Cancer; oxLDL; Lipid metabolism; Tumor immunology; LOW-DENSITY-LIPOPROTEIN; FATTY-ACID UPTAKE; PANCREATIC ADENOCARCINOMA; TUMOR MICROENVIRONMENT; METABOLIC ADAPTATION; BINDING-SITE; RECEPTOR; CELLS; DEFICIENCY; ACTIVATION;
D O I
10.1016/j.imlet.2023.12.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The membrane protein CD36 is a lipid transporter, scavenger receptor, and receptor for the antiangiogenic protein thrombospondin 1 (TSP1). CD36 is expressed by cancer cells and by many associated cells including various cancer-infiltrating immune cell types. Thereby, CD36 plays critical roles in cancer, and it has been reported to affect cancer growth, metastasis, angiogenesis, and drug resistance. However, these roles are partly contradictory, as CD36 has been both reported to promote and inhibit cancer progression. Moreover, the mechanisms are also partly contradictory, because CD36 has been shown to exert opposite cellular effects such as cell division, senescence and cell death. This review provides an overview of the diverse effects of CD36 on tumor progression, aiming to shed light on its diverse pro- and anti-cancer roles, and the implications for therapeutic targeting.
引用
收藏
页码:7 / 15
页数:9
相关论文
共 50 条
  • [31] Platelets in aging and cancer—“double-edged sword”
    Alessandra V. S. Faria
    Sheila S. Andrade
    Maikel P. Peppelenbosch
    Carmen V. Ferreira-Halder
    Gwenny M. Fuhler
    Cancer and Metastasis Reviews, 2020, 39 : 1205 - 1221
  • [32] cGAS and cancer therapy: a double-edged sword
    Du, Jia-min
    Qian, Mei-jia
    Yuan, Tao
    Chen, Rui-han
    He, Qiao-jun
    Yang, Bo
    Ling, Qi
    Zhu, Hong
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (09) : 2202 - 2211
  • [33] Glutathione in Ovarian Cancer: A Double-Edged Sword
    Nunes, Sofia C.
    Serpa, Jacinta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)
  • [34] The Double-Edged Sword of Autophagy Modulation in Cancer
    White, Eileen
    DiPaola, Robert S.
    CLINICAL CANCER RESEARCH, 2009, 15 (17) : 5308 - 5316
  • [35] Pericytes: a double-edged sword in cancer therapy
    Meng, Mao-Bin
    Zaorsky, Nicholas G.
    Deng, Lei
    Wang, Huan-Huan
    Chao, Jiang
    Zhao, Lu-Jun
    Yuan, Zhi-Yong
    Ping, Wang
    FUTURE ONCOLOGY, 2015, 11 (01) : 169 - 179
  • [36] Double-Edged Sword of the New Cancer Therapeutics
    Force, Thomas
    CIRCULATION, 2012, 125 (17) : 2057 - 2058
  • [37] The double-edged sword of Notch signaling in cancer
    South, Andrew P.
    Cho, Raymond J.
    Aster, Jon C.
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2012, 23 (04) : 458 - 464
  • [38] cGAS and cancer therapy: a double-edged sword
    Jia-min Du
    Mei-jia Qian
    Tao Yuan
    Rui-han Chen
    Qiao-jun He
    Bo Yang
    Qi Ling
    Hong Zhu
    Acta Pharmacologica Sinica, 2022, 43 : 2202 - 2211
  • [39] PPARs: A Double-Edged Sword in Cancer Therapy?
    Panigrahy, Dipak
    Kapainen, Arja
    Kieran, Mark W.
    Huang, Sui
    PPAR RESEARCH, 2008, 2008
  • [40] Testicular Cancer and Platinum: A Double-Edged Sword
    O'Reilly, Aine
    MacEneaney, Peter
    Mayer, Nick
    O'Reilly, Seamus P.
    Power, Derek G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : E46 - E48